stockrowBridgeBio Pharma, Inc.
BBIO Healthcare Biotechnology
BridgeBio Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $502.1 million, up 126.3% from fiscal 2024.
- Revenue
- +192.6%
- EPS
- +55.8%
- Free cash flow
- +60.5%
- Total debt
- +4.21%
Quarter to September 2026, against a year earlier
Follow BBIO
Alert me
BridgeBio Pharma, Inc. (BBIO) Total debt
BridgeBio Pharma, Inc.'s total debt at the end of fiscal 2025 was $1.9B, up 7.62% from $1.7B in fiscal 2024. At the end of the quarter to 30 September 2026 it was $1.9B. Over the past ten years it has ranged from $54.5M (fiscal 2018) to $1.9B (fiscal 2025) — the current reading is the highest in ten years. BridgeBio Pharma, Inc. ranks 9th of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $1.9B | 7.62% |
| FY2024 | $1.7B | (0.31%) |
| FY2023 | $1.7B | 1.12% |
| FY2022 | $1.7B | 0.22% |
| FY2021 | $1.7B | 256.96% |
| FY2020 | $477.3M | 378.31% |
| FY2019 | $99.8M | 83.08% |
| FY2018 | $54.5M | (62.15%) |
| FY2017 | $144.0M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $1.9B | 0.08% |
| Jun 2026 | $1.9B | 0.08% |
| Mar 2026 | $1.9B | 3.97% |
| Dec 2025 | $1.9B | 0.08% |
| 26 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| JAZZ Jazz Pharmaceuticals PLC compare | $5.6B |
| BMRN BioMarin Pharmaceutical Inc. compare | $4.2B |
| HALO Halozyme Therapeutics, Inc. compare | $3.3B |
| BBIO BridgeBio Pharma, Inc. | $1.9B |
| ASND Ascendis Pharma A/S compare | $523.3M |
| TECH Bio-Techne Corp compare | $200.0M |
| EXEL Exelixis, Inc. compare | $191.0M |
| SMMT Summit Therapeutics PLC compare | $100.0M |
| KYMR Kymera Therapeutics, Inc. compare | $602.0K |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on BBIO
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement